title: Biomodulatory metronomic therapy induces PET-negative remission in chemo- and brentuximab-refractory Hodgkin lymphoma.
authors.affiliation: Department of Internal Medicine III, Haematology & Oncology, University Hospital of Regensburg, Regensburg, Germany.
authors.forename: Peter
authors.initials: P
authors.lastname: Ugocsai
authors.affiliation: Department of Internal Medicine III, Haematology & Oncology, University Hospital of Regensburg, Regensburg, Germany.
authors.forename: Daniel
authors.initials: D
authors.lastname: Wolff
authors.affiliation: Department of nuclear Medicine, University Hospital of Regensburg, Regensburg, Germany.
authors.forename: Karin
authors.initials: K
authors.lastname: Menhart
authors.affiliation: Department of nuclear Medicine, University Hospital of Regensburg, Regensburg, Germany.
authors.forename: Dirk
authors.initials: D
authors.lastname: Hellwig
authors.affiliation: Department of Internal Medicine III, Haematology & Oncology, University Hospital of Regensburg, Regensburg, Germany.
authors.forename: Ernst
authors.initials: E
authors.lastname: Holler
authors.affiliation: Department of Internal Medicine III, Haematology & Oncology, University Hospital of Regensburg, Regensburg, Germany.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Herr
authors.affiliation: Department of Internal Medicine III, Haematology & Oncology, University Hospital of Regensburg, Regensburg, Germany. albrecht.reichle@ukr.de.
authors.forename: Albrecht
authors.initials: A
authors.lastname: Reichle
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000079963:Brentuximab Vedotin; D004334:Drug Administration Schedule; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage; D007155:Immunologic Factors / Q000008:administration & dosage; D008297:Male; D049268:Positron-Emission Tomography; D012074:Remission Induction; D016879:Salvage Therapy / Q000379:methods
chemical_list: D018796:Immunoconjugates; D007155:Immunologic Factors; D000079963:Brentuximab Vedotin
keywords: biomodulatory therapy; everolimus; metronomic therapy; pioglitazone; refractory Hodgkin lymphoma